Covered recipient · General Payments record
MARSHALL POSNER
Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology
General Payments · PY2018–2024
$104,449.38
- Reported across 67 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Consulting Fee | $13,408.00 | 8 |
| Food and Beverage | $504.92 | 7 |
| Education | $18.09 | 1 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Merck Sharp & Dohme Corporation | $13,426.09 | 9 |
| Coherus Biosciences Inc. | $420.77 | 4 |
| Tempus AI, Inc | $67.46 | 2 |
| IBSA Pharma Inc. | $16.69 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (16)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| Coherus Biosciences Inc. | $140.35 | 03/01/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1147276452 | CMS |
| Coherus Biosciences Inc. | $51.99 | 03/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1147274692 | CMS |
| Coherus Biosciences Inc. | $142.27 | 06/01/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1147276450 | CMS |
| Coherus Biosciences Inc. | $86.16 | 11/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1147276818 | CMS |
| IBSA Pharma Inc. | $16.69 | 09/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1142973517 | CMS |
| Merck Sharp & Dohme LLC | $3,175.00 | 02/05/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1141765804 | CMS |
| Merck Sharp & Dohme LLC | $1,200.00 | 09/16/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1141765800 | CMS |
| Merck Sharp & Dohme LLC | $1,950.00 | 09/18/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1141765802 | CMS |
| Merck Sharp & Dohme LLC | $900.00 | 09/18/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1141891694 | CMS |
| Merck Sharp & Dohme LLC | $800.00 | 10/01/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1141768367 | CMS |
| Merck Sharp & Dohme LLC | $1,921.50 | 10/02/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1141591618 | CMS |
| Merck Sharp & Dohme LLC | $3,294.00 | 10/09/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1141591620 | CMS |
| Merck Sharp & Dohme LLC | $18.09 | 10/22/2024 | Education | Undisputed | 01/23/2026 | 1141565052 | CMS |
| Merck Sharp & Dohme LLC | $167.50 | 12/16/2024 | Consulting Fee | Undisputed | 01/23/2026 | 1141564425 | CMS |
| Tempus AI, Inc | $51.69 | 05/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1150172169 | CMS |
| Tempus AI, Inc | $15.77 | 07/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1150172171 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.